Perspective
Nature Reviews Immunology 7, 650-654 (August 2007) | doi:10.1038/nri2137
Focus on: Immune tolerance
Viewpoint: What does the future hold for cell-based tolerogenic therapy?
Jeffrey A. Bluestone, Angus W. Thomson, Ethan M. Shevach & Howard L. Weiner1 About the authors
Abstract
Evidence from animal models has shown that the transfer of regulatory T cells or tolerogenic dendritic cells can prevent or cure transplant rejection or re-establish self-tolerance in autoimmune disease. The potential of these tolerogenic cells for the treatment of T-cell-mediated diseases in humans has gained momentum in recent years. Here, Nature Reviews Immunology asks four leading researchers to provide their view on the future of cell-based tolerogenic therapy and to highlight some important issues that must be considered before this form of immunotherapy can become a reality.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
RESEARCH
Dendritic Cell-Based Tumor Vaccines and Antigen Presentation AttenuatorsMolecular Therapy Research Article